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Abstract
Background: The relationship between right ventricle (RV), extracellular matrix (ECM) fibrosis and 
fibrosis-linked, circulating microRNAs in dilated cardiomyopathy (DCM) is unknown.
Aim: The aim of the study was to uncover the associations between serum markers of ECM metabolism 
and circulating microRNAs with RV morphological and functional parameters. 
Methods: The study population consisted of 70 consecutive DCM patients (ejection fraction 24.4 ± 
± 7.4%). Based on detailed echocardiographic assessment — 15 patients had normal RV, whereas  
55 patients had RV dilatation (RVD) and/or RV systolic dysfunction (RVSD). Procollagens type I and III 
carboxy- and amino-terminal peptides, osteopontin (OPN), TGF1-b1, connective tissue growth factor 
(CTGF), MMP-2, MMP-9 and TIMP-1 were measured in serum as well as expression of miR-21, miR-26,  
miR-29, miR-30 and miR-133a. All patients underwent endomyocardial biopsy.
Results: Biopsy-proven fibrosis was evenly distributed in two groups. Serum levels of fibrosis markers 
did not differ between groups. OPN, CTGF, MMP-2, and TIMP-1 correlated with RV parameters. Only 
miR-133 a was differently expressed in both groups. MiR-21, miR-26, miR-30, and miR-133a cor-
related with RV morphological but without functional parameters. Not a single marker of fibrosis was 
independently associated with RV. MiR-30 was associated with RV impairment in the logistic regression 
model adjusted for age, sex, body mass index, and disease duration; however, lost its significance in the 
more comprehensive model. 
Conclusions: Right ventricle structural and functional abnormalities are common in DCM. ECM 
fibrosis and serum markers are not associated with RV impairment. The prognostic value of studied 
microRNAs on RV is limited in DCM. (Cardiol J 2018; 25, 6: 722–731)
Key words: dilated cardiomyopathy, right ventricle, biopsy, extracellular matrix  
fibrosis, microRNA
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Introduction
Dilated cardiomyopathy (DCM) is primarily 
characterized by left ventricular (LV) wall thin-
ning, chamber dilation and systolic dysfunction [1]. 
However, accompanying right ventricular (RV) 
involvement is frequently observed in DCM, and is 
related to poorer outcomes [2]. Precise measure-
ment of LV morphology and function is relatively 
straightforward and based on solid geometric prin-
ciples. On the other hand, due to its unique cres-
cent shape, evaluation of RV size and function is far 
more demanding than its LV counterpart. Recent 
recommendations from the European Association 
of the Cardiovascular Imaging (EACVI) emphasize 
the importance of correct RV measurements [3]. 
Fibrosis of the extracellular matrix (ECM) 
is one of the hallmarks of DCM ultrastructural 
pathology. The gold standard is endomyocardial 
biopsy (EMB) and the detailed assessment of car-
diac samples under a microscope. Taking another 
approach, an insight into the dynamics of ECM 
fibrosis can be provided with the assessment of 
blood levels of ECM metabolism markers, such as 
indices of collagen synthesis, fibrosis controlling 
factors, including osteopontin (OPN), transforming 
growth factor beta (TGF-b) or connective tissue 
growth factor (CTGF), and an antagonistic system 
of matrix metalloproteinases (MMPs) and their 
tissue inhibitors (TIMPs) [4]. 
Aside from these markers, there exist micro-
RNAs: small (22 nucleotides) non-coding RNA 
sequences that bind to messenger RNA (mRNA) 
and inhibit protein translation or degrade mRNA. 
These are considered to be factors playing a vital 
role in the majority of cellular processes [5]. Among 
numerous candidates, up to the present, a set of 
five microRNAs: miR-21, miR-26, miR-29, miR-30, 
and miR-133a have been linked to cardiac fibrosis 
[6, 7]. Additionally, we have recently compared ex-
pression of those circulating, fibrosis-linked micro-
RNAs between DCM patients and healthy controls. 
Except for miR-133a, all of studied microRNAs 
were differently expressed in DCM compared to 
controls [7].
The left and right ventricles differ substan-
tially in terms of morphology and function [8]. 
Similarly, molecular mechanisms leading to RV 
failure partly differ from those for LV pathology [9]. 
The relationship between RV abnormalities 
and ECM fibrosis, serum markers of fibrosis, and 
circulating fibrosis-linked microRNAs is largely 
unknown in DCM. 
Therefore, the aim of the study was to test the 
hypothesis that the level of ECM fibrosis, serum 
levels of ECM metabolism markers and the profile 
of circulating microRNAs (miR-21, miR-26, miR-29, 
miR-30 and miR-133a) are dissimilar in DCM 
patients with and without RV abnormalities. Fur-
thermore, we sought to uncover the associations 
between serum markers of ECM metabolism and 
circulating microRNAs with RV morphological and 
functional parameters. 
Methods
Study population 
From July 2014 to October 2015 70 consecu-
tive DCM patients fulfilling pre-specified criteria 
and were willing to participate in the study were 
included. DCM was diagnosed in accordance with 
current recommendations having excluded signifi-
cant coronary artery disease, primary heart valve 
disease, congenital heart disease, and arterial hy-
pertension [1]. Based on detailed echocardiograms, 
all patients fulfilled strict morphological and func-
tional criteria, e.g. all had dilated and significantly 
depressed systolic function (ejection fraction [EF] 
< 35%) [10]. All patients had experienced stable 
heart failure (HF) symptoms, consistent with the 
New York Heart Association (NYHA) class I–III, for 
at least 2 weeks prior to the study. Disease dura-
tion was defined as the time elapsed from the first 
formal diagnosis of DCM to the point of recruit-
ment in the present study. The study protocol was 
approved by the relevant institutional committees 
and the Ethical Committee. All patients gave writ-
ten informed consent prior to inclusion in the study. 
Echocardiograpic assessment  
of RV morphology and function
All measurements were performed according to 
the most recent recommendations of the EACVI [3]. 
Examinations were performed on commercially avail-
able equipment (Vivid 7 GE Medical System, Horten, 
Norway) with a phased-array of 1.5–4 MHz transducer.
Based on recent EACVI guidelines, a con-
servative approach was followed and diagnosed RV 
dilatation (RVD) when both the basal RV dimension 
(RVd1) was above 41 mm, and the mid-cavity RV 
dimension (RVd2) was > 35 mm. In addition, RV 
systolic dysfunction (RVSD) was diagnosed if tricus-
pid annular plane systolic excursion (TAPSE) was 
below 17 mm and pulsed Doppler tissue imaging- 
-derived tricuspid lateral annular systolic velocity 
(RV-S’) < 9.5 cm/s [3].
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Endomyocardial biopsy
Endomyocardial biopsy procedures were per-
formed by experienced operators via a femoral or 
jugular vein approach [11]. Long (104 cm), flex-
ible, disposable biopsy forceps 7 French size with 
small jaws (Cordis®, Johnson & Johnson Co, Miami 
Lakes, FL, USA) were used for the procedure. 
Up to 5 myocardial samples were obtained from 
the RV septum, which were immediately stored 
in formalin for light microscopic examinations 
(2–3 samples) and snap-frozen in optimal cutting 
temperature-embedding medium and stored at 
–80°C for further studies (2 samples). The pres-
ence of fibrosis was determined in 2–3 samples by 
an experienced pathologist blinded to the clinical 
data. Collagen volume fraction (CVF) was assessed 
by quantitative morphometry in biopsy sections 
stained with collagen specific picro-sirius red. CVF 
was defined as the percentage red-stained area per 
total myocardial tissue area [12].
Serum markers of collagen metabolism
Venous blood samples were drawn on the day 
of the study after a 30-min supine rest in a fasted 
state in the morning. After centrifuge, supernatant 
was stored at –20°C until assay. The concentra-
tions of collagen synthesis markers and markers 
of collagen degradation were determined in plasma 
using a commercially available ELISA tests as 
follows: collagen type 1, procollagen I N-terminal 
propeptide (PINP), procollagen III N-terminal 
propeptide (PIIINP), procollagen I C-terminal 
propeptide (PICP), procollagen III C-terminal 
propeptide (PIIICP), CTGF (all from Cloud Clone 
Corp. Houston, TX, USA); RayBio MMP2 ELISA, 
RayBio MMP9 ELISA, and RayBio TIMP-1 ELISA 
(all from RayBiotech, Norcross, GA, USA) and 
TGF-b (Diaclone SAS, Besancon Cedex, France). 
All measurements were performed by technicians 
blinded to the sample status. Intra-assay and inter-
assay coefficients of variation were < 7%. 
Circulating microRNAs
The quantitative polymerase chain reaction 
procedure used to measure microRNA levels and 
was performed as described previously [13]. RNA 
was extracted from 100 µL of plasma using a Mir-
Vana kit (Life Technologies) following the manufac-
turer’s protocol. 2 µL of extracted RNA was used 
to perform reverse transcription with a TaqMan 
Advanced MicroRNA cDNA Synthesis Kit (Life 
Technologies). cDNA samples were  diluted 10× 
before the qPCR reaction. qPCR was conducted 
on 384-well plates with TaqMan Advanced Mas-
terMix and TaqMan Advanced Assays targeting: 
hsa-miR-21-5p, hsa-mir-26a-5p, hsa-miR-29b-3p, 
hsa-miR-30c-5p, and hsa-miR-133a-3p. 15 mL reac-
tions were prepared with pipetting station Bravo 
(Agilent Technologies) and a real-time reaction 
was run and read on a CFX384 Real Time PCR 
Detection System (Bio-Rad). Mean Cq values were 
normalized to the geometric mean of hsa-miR- 
-15b-5p and hsa-miR-16-5p, which were selected 
as relatively stable controls in pilot experiments. 
Normalized data was expressed for each sample 
as [2–DCq] where DCq is the difference between the 
Cq value between the microRNA of interest and 
the geometric mean of miR-15b and miR-16 for 
a particular sample.
Statistical analysis
The distribution of variables was assessed 
with the Shapiro-Wilk test. Comparisons of clini-
cal parameters within groups were conducted 
with the t-Student test or with Mann-Whitney 
tests if any lack of normality was found therein. 
Univariate relationships between RV parameters 
and serum markers of fibrosis and microRNAs 
were determined by Pearson correlation analysis. 
Associations between serum markers of fibrosis 
and circulating microRNAs with RV morphologi-
cal and functional parameters were analyzed with 
logistic regression methods. Three logistic regres-
sion models were analyzed: an unadjusted model 
(1st model), a model with adjustments for age, sex, body 
mass index (BMI) and disease duration (2nd model), 
and the most comprehensive model, with adjust-
ments for age, sex, BMI, disease duration, EF, 
right atrium (RA) area, ECM fibrosis, pulmonary 
hypertension, and N-terminal B-type natriuretic 
peptide (NT-proBNP) (3rd model). All results were 
considered statistically significant when p was 
< 0.05. The entire analysis was performed using 
the SPSS package, version 14.0 (SPSS Inc., Chi-
cago, Illinois) and R 3.1.2 (R Foundation for Statisti-
cal Computing, Vienna, Austria).
Results
Baseline characteristics
Based on RV measurements, patients were 
divided into two groups: those with normal RV 
dimensions and preserved systolic function (group 
1, n = 15, 21.4%), and those with RVD and/or 
RVSD (group 2, n = 55, 78.6%). Table 1 shows 
the baseline characteristics of these two groups. 
Patients with normal RV were found to have a sig-
nificantly shorter duration of disease compared to 
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Table 1. Baseline characteristics of the study population, divided into those with normal right ventricle  
dimensions and systolic function (group 1), and those with right ventricle  dilatation and/or systolic 
dysfunction (group 2). 
Parameter Group 1  
(n = 15, 21.4%)
Group 2  
(n = 55, 78.6%)
P
Age [years] 45.6 ± 12.1 48.7 ± 12.1 0.38
Sex [male/female] 12 (80%)/3 (20%) 51 (92.7%)/4 (7.3%) 0.14
BMI [kg/m2] 27.9 ± 6.5 27 ± 5 0.54
NYHA class 2.47 ± 0.83 2.6 ± 0.71 0.54
Duration of disease [months] 4.1 ± 5.7 29.8 ± 38.3 < 0.001
QRS [ms] 102.7 ± 36.3 112.1 ± 32.6 0.34
LVESd/BSA [mm/m2] 26.6 ± 5.1 31 ± 7.3 0.03
LVEDd/BSA [mm/m2] 32.7 ± 3.7 36.4 ± 7.5 0.01
LVESvol/BSA [mL/m2] 79.6 ± 39.1 100.1 ± 50.6 0.18
LVEDvol/BSA [mL/m2] 111.8 ± 47.9 130.4 ± 62.1 0.32
Ejection fraction [%] 26.8 ± 6.6 23.7 ± 7.5 0.15
E/E’ (average sep+lat) 15.6 ± 5.9 21.5 ± 12.2 0.02
RVOT prox [mm] 28.7 ± 6.7 32.9 ± 7.3 0.06
RVd1 [mm] 30.2 ± 4.9 37.3 ± 8.2 0.007
RVd2 [mm] 24.9 ± 6.9 33.7 ± 7.9 0.001
RVd3 [mm] 76.2 ± 7.2 83.8 ± 15.8 0.1 
RV thickness [mm] 3.7 ± 1.1 3.9 ± 1.1 0.67
TAPSE [mm] 23.6 ± 6.1 15.3 ± 3.9 0.008
RV-S’ [cm/s] 11.8 ± 3.2 7.6 ± 2.8 < 0.001
LA area [cm2] 26.7 ± 9.3 31.7 ± 8.2 0.05
RA area [cm2] 19.9 ± 5.4 25.2 ± 8 0.05
PASP [mmHg] 33.4 ± 7.7 41.5 ± 16.7 0.01
ECM fibrosis 4 (26.7%) 20 (36.4%) 0.48
CVF [%] 5.3 ± 3.4 6 ± 6.5 0.83
CI [mL/min/m2] 2.3 ± 0.5 1.9 ± 0.46 0.002
PA mean [mmHg] 17.4 ± 5.4 24.4 ± 11.4 0.002
PA saturation [%] 68.4 ± 4.3 61.7 ± 8.7 < 0.001
PCWP mean [mmHg] 10.5 ± 6.3 16.6 ± 8.3 0.02
Ao mean [mmHg] 91.3 ± 10.8 89.7 ± 14.5 0.71
Pulmonary hypertension 1 (7.1%) 26 (47.3%) 0.006
VO2peak [mL/kg/min] 19 ± 5.5 16.2 ± 6.1 0.33
Hemoglobin [g/dL] 14.5 ± 1.6 14.4 ± 1.6 0.96
hs-troponin T [ng/mL] 0.0145 ± 0.0096 0.0243 ± 0.0194 0.09
NT-proBNP [pg/mL] 2881.3 ± 7006 3503.5 ± 5005 0.71
Beta-blocker 15 (100%) 54 (98.2%) 0.6
ACE-I or ARB 15 (100%) 54 (98.2%) 0.6
MRA 15 (100%) 51 (92.7%) 0.28
CRT-D 2 (13.3%) 25 (45.5%) 0.02 
BMI — body mass index; NYHA — New York Heart Association class; LVESd/BSA — left ventricular end-systolic diameter indexed to body 
surface area; LVEDd/BSA — left ventricular end-diastolic diameter indexed to body surface area; LVESvol/BSA — left ventricular end-systolic 
volume indexed to body surface area; LVEDvol/BSA — left ventricular end-diastolic volume indexed to body surface area; E/E’ (average 
sep+lat) — ratio of early mitral inflow E-wave and early myocardial E’ velocity (E’ — is an average of septal and lateral myocardial velocity); 
RVOT — right ventricular outflow tract; RVd1;2;3 — right ventricular measurements from the apical four-chamber view; TAPSE — tricuspid 
annular plane systolic excursion; RV-S’ — pulsed DTI-derived tricuspid lateral annular systolic velocity; LA area/RA area — left and right atrial 
area; PASP — pulmonary artery systolic pressure; ECM fibrosis  — extracellular matrix fibrosis; CVF — collagen volume fraction; CI — cardiac 
index; PA mean — mean pulmonary artery pressure; PCWP — pulmonary artery wedge pressure; Ao mean — mean aortic pressure; VO2peak 
— peak oxygen uptake; hs-troponin T — high sensitivity troponin T; NT-proBNP — N-terminal pro B-type natriuretic peptide; ACE-I — angio-
tensin converting enzyme inhibitor; ARB — angiotensin receptor type 1 blocker; MRA — mineralocorticoid receptor antagonist; CRT-D —  
cardiac resynchronization therapy with cardioverter-defibrillator
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those with RVD and/or RVSD (4.1 ± 5.7 vs. 29.8 ± 
± 38.3 months, p < 0.001, respectively). Those 
patients with impaired RV had significantly worse 
LV diastolic function. Not surprisingly, RV basal 
and mid-cavity diameters (RVd1 and RVd2) were 
significantly enlarged in group 2 patients as were 
indices of RV systolic function — TAPSE and RV-
S’; nonetheless, RV outflow tract (RVOT) proximal 
diameter, RV longitudinal diameter (RVd3), and RV 
free wall thickness were found to be similar in both 
groups. Patients from group 2 were more often di-
agnosed with secondary pulmonary hypertension. 
ECM fibrosis as well as the magnitude of fibrosis, 
as quantified with CVF, were evenly distributed 
between the two groups. 
Comparison of markers of fibrosis  
and microRNAs between patients  
with normal and impaired RV
There were no differences in all studied serum 
markers of fibrosis between the two groups (Table 2), 
whereas out of the five microRNAs under study, 
only miR-133a in [2–DCq] units were differently 
expressed in patients with normal and abnormal 
RV (Table 3). 
Correlations between markers  
of ECM fibrosis and RV parameters 
RVd1 and RVd2, correlated with OPN and 
MMP-2 or MMP-2 and TIMP-1, respectively 
(Table 4). Interestingly, the remaining RV ana-
Table 2. Comparison of serum markers of fibrosis between dilated cardiomyopathy patients with  
normal and abnormal right ventricle.
Parameter Group 1 (n = 15, 21.4%) Group 2 (n = 55, 78.6%) P
PICP [ng/mL] 0.15 (0.08–0.28) 0.18 (0.06–0.46) 0.67
PINP [pg/mL] 125.4 (78.4–380.1) 131 (25.2–1050) 0.69
PIIICP [pg/mL] 261.1 (87.2–1165) 195.7 (70.3–937.2) 0.2
PIIINP [ng/mL] 4.4 (2.4–5.1) 4.4 (2.2–6.1) 0.92
Col-1 [pg/mL] 83.4 (35.3–206.5) 56.4 (23.1–233.4) 0.13
OPN [ng/mL] 2.9 (1.87–7.91 3.18 (0.74–19.4) 0.5
TGF-b1 [ng/mL] 2.71 (1.36–5.73) 2.2 (0.65–6.9) 0.3
CTGF [ng/mL] 3.56 (1.21–12.4) 3.8 (0.5–23.9) 0.61
MMP-2 [ng/mL] 5.9 (2.9–7.4) 6.1 (2.7–14.8) 0.23
MMP-9 [ng/mL] 2.2 (0.28–5.2) 1.9 (0.3–9.2) 0.81
TIMP-1 [ng/mL] 15.3 (1.9–32.5) 15.1 (1.8–36.2) 0.56
Data are presented as median (range); PICP — procollagen I C-terminal propeptide; PINP — procollagen I N-terminal propeptide; PIIICP — 
procollagen III C-terminal propeptide; PIIINP — procollagen III N-terminal propeptide; Col-1 — collagen type 1; OPN — osteopontin;  
TGFb — transforming growth factor beta; CTGF — connective tissue growth factor; MMP — matrix metalloproteinase; TIMP — tissue  
inhibitor of matrix metalloproteinase
Table 3. Comparison of circulating microRNAs between dilated cardiomyopathy patients with normal 
and abnormal right ventricle.
Parameter Group 1 (n = 15) Group 2 (n = 55) P
mir-21 [DCq] 0.19 ± 0.48 0.12 ± 0.64 0.69
mir-21 [2–DCq] 0.92 ± 0.27 1.01 ± 0.49 0.48
mir-26 [DCq] –0.102 ± 0.87 –0.032 ± 0.78 0.77
mir-26 [2–DCq] 1.25 ± 0.69 1.18 ± 0.67 0.7
mir-29 [DCq] 3.03 ± 0.61 2.72 ± 0.8 0.17
mir-29 [2–DCq] 0.13 ± 0.05 0.17 ± 0.088 0.1 
mir-30a [DCq] 8.43 ± 1.95 7.64 ± 1.57 0.12
mir-30a [2–DCq] 0.82 ± 0.018 0.9 ± 0.011 0.84
mir-133a [DCq] 8.05 ± 1.48 7.38 ± 2.47 0.32
mir-133a [2–DCq] 0.6 ± 0.07 1.41 ± 0.2 0.006
Data are presented as mean ± standard deviation
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tomical parameters, including RVOT proximal 
diameter, RVd3, and RV wall thickness, were not 
seen to correlate with any marker of fibrosis. As 
for RV systolic function parameters, only TAPSE 
correlated with CTGF; in contrast to this, RV-S’ 
showed no correlation with any marker of fibrosis. 
Finally, pulmonary artery systolic pressure (PASP) 
correlated with OPN and MMP-2. It should be 
noted that not a single marker of collagen synthesis 
(PICP, PINP, PIIICP, PIIINP, and col-1) correlated 
with any RV parameter. 
Correlations between circulating  
microRNAs and RV parameters 
In terms of RV anatomical parameters, miR-30 
correlated with RVOT proximal diameter, RVd1 and 
RA area (Table 5). Additionally, miR-21 correlated 
with RVd2, and miR-133a correlated with RVd3 
and RV wall thickness. Importantly, no microRNA 
correlated with RV systolic function parameters, 
including TAPSE and RV-S’. 
Associations between markers of ECM  
fibrosis and microRNAs with RV parameters
It was  verified as to whether there were any 
independent associations between serum mark-
ers of fibrosis and circulating microRNAs with RV 
parameters. There were no markers of fibrosis 
independently associated with RV morphological 
and functional parameters (Table 6). Out of the five 
microRNAs studied, only miR-30 was associated 
with RV impairment (OR 0.41; p < 0.02) in the 2nd 
model (Table 7). However, this link was no longer 
observed in the 3rd model, which had been adjusted 
for more powerful RV-associated variables.  
Discussion
The distribution of ECM fibrosis as well as the 
magnitude of fibrosis was similar in patients with 
and without RV abnormalities. Second, no differ-
ences in serum levels of ECM metabolism markers 
were observed between DCM patients with and 
without RVD and/or RVSD. Thirdly, expression 
levels of only one out of  five fibrosis-linked cir-
culating microRNAs — namely miR-133a — was 
different when comparing patients with and without 
RV abnormalities. Fourthly, RV morphological and 
functional parameters correlated with only a few 
markers of ECM fibrosis, including OPN and CTGF 
and MMPs/TIMPs system. Remarkably, none of the 
RV parameters correlated with markers of collagen 
synthesis. In addition, it was found that circulat-
ing microRNAs correlated with RV morphological 
indices; however, no correlations were observed 
between microRNAs and RV systolic function pa-
rameters, including TAPSE and RV-S’. Not a single 
marker of ECM fibrosis was independently associ-
ated with RV abnormalities. Finally, only mir-30 
was associated with RV impairment in the logistic 
regression model adjusted for age, sex, BMI, and 
disease duration; however, this association was 
no longer observed in the 3rd model which was ad-
ditionally adjusted for EF, RA area, ECM fibrosis, 
pulmonary hypertension, and NT-proBNP.
Associations between ECM fibrosis, markers 
of ECM metabolism and RV parameters 
Before more detailed results can be inter-
preted, it is important to know the relations of 
serum markers of ECM metabolism between 
DCM and controls. It was previously presented 
that among markers of collagen synthesis, only 
PIIINP was significantly higher in DCM, whereas 
PICP, PINP, and PIIICP were similar in DCM and 
controls. OPN and CTGF levels were higher in 
DCM but levels of TGF-b1 did not differ between 
DCM and controls. MMP-2, MMP-9 and TIMP-1 
were significantly higher in DCM [14]. There are 
no studies directly addressing the relationship 
between ECM fibrosis and serum markers of ECM 
metabolism with RV morphology and function in 
DCM. Past studies have shown that the percentage 
of myocardial collagen type I, III and IV significantly 
differs between LV and RV in DCM, and the same 
has been discovered for expressions of MMP-1, 
MMP-2, and MMP-9 [15]. These established find-
ings support the hypothesis that distinct patterns of 
ECM structure, and particular turnover pathways, 
exist in the RV and LV [16]. Further empirical 
evidence for this was provided by Tyagi et al. [17], 
who observed differences in collagenolytic MMPs 
activity between LV and RV, both after myocardial 
infarction and in DCM. Another result found that 
LV unloading, with LV assist devices, decreased 
RV total collagen and myocardial TNF-a content. 
Thus, a decrease in ECM fibrosis and normaliza-
tion of cytokine up-regulation is an important effect 
of mechanical unloading associated with both LV 
and RV recovery [18]. Present observations report 
a lack of associations between ECM fibrosis, serum 
markers of fibrosis and RV morphology and func-
tion. In endeavoring to explain these findings, the 
following was postulated. On the one hand, it may 
be that the serum markers of ECM fibrosis under 
study are imperfect tools for a reliable assessment 
of dynamics of ECM fibrosis; on the other hand, 
substantial differences were observed in those 
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markers between DCM and controls. Although 
ECM turnover is clearly increased in DCM, no 
direct links between ECM fibrosis and RV impair-
ment were observed. This observation is important 
as it helps to understand why specific anti-fibrotic 
therapies, tested in HF and DCM, did not translate 
into substantial improvements in RV morphology 
and function. Furthermore, the fact that the per-
centage of patients with fibrosis is similar whether 
with and without RV abnormalities which may 
suggest that once ECM fibrosis starts (probably 
very early on in the course of the disease) it is 
homogenously increased in all DCM patients. 
Associations between circulating microRNAs 
and RV morphology and function 
As the process of LV and RV adaptation to 
stress and loading conditions differ substantially, 
chamber-specific microRNAs patterns are to be 
expected. In a recent study, Kakimoto et al. [19] 
showed prominent micro-RNA chamber-specificity, 
and found that, out of 438 microRNAs studied, 
Table 7. Value of serum markers of fibrosis in predicting right ventricle dilatation and/or systolic  
dysfunction in an unadjusted (1st model) and adjusted models: (2nd model) adjusted for age, sex, body 
mass index and disease duration, and (the 3rd model) additionally adjusted for ejection fraction, right 
atrial area, extracellular matrix fibrosis, pulmonary hypertension, and NT-proBNP.
Parameter Model 1 Model 2 Model 3
mir-21 [DCq] OR = 0.825; p = 0.694 OR = 0.443; p = 0.211 OR = 0.005; p = 0.628 
mir-21 [2–DCq] OR = 1.708; p = 0.471 OR = 5.011; p = 0.156 OR ≥ 100; p = 0.494 
mir-26 [DCq] OR = 1.118; p = 0.763 OR = 0.905; p = 0.87 OR ≥ 100; p = 0.995 
mir-26 [2–DCq] OR = 0.848; p = 0.698 OR = 1.157; p = 0.842 OR ≤ 0.00001; p = 0.994 
mir-29 [DCq] OR = 0.612; p = 0.19 OR = 0.672; p = 0.523 OR ≤ 0.00001; p = 0.997 
mir-29 [2–DCq] OR ≥ 100; p = 0.11 OR = 36.439; p = 0.549 OR ≥ 100; p = 0.997 
mir-30 [DCq] OR = 0.738; p = 0.125 OR = 0.41; p = 0.023* OR ≤ 0.00001; p = 0.999 
mir-30 [2–DCq] OR ≥ 100; p = 0.835 OR ≥ 100;p = 0.067 OR ≥ 100; p = 0.999 
mir-133a [DCq] OR = 0.883; p = 0.319 OR = 0.83; p = 0.336 OR ≥ 100; p = 0.974 
mir-133a [2–DCq] OR ≥ 100; p = 0.12 OR ≥ 100; p = 0.29 OR ≥ 100; p = 0.999
* < 0.05
Table 6. Value of serum markers of fibrosis in predicting right ventricle dilatation and/or systolic  
dysfunction in an unadjusted (1st model) and adjusted models: (2nd model) adjusted for age, sex, body 
mass index and disease duration, and (the 3rd model) additionally adjusted for ejection fraction, right 
atrial area, extracellular matrix fibrosis, pulmonary hypertension, and NT-proBNP.
Parameter Model 1 Model 2 Model 3
PICP [ng/mL] OR = 0.834; p = 0.514 OR = 0.935; p = 0.852 OR = 0.062; p = 0.629 
PINP [pg/mL] OR = 0.99993; p = 0.971 OR = 0.998; p = 0.554 OR = 0.487; p = 0.996 
PIIICP [ng/mL] OR = 0.29; p = 0.328 OR = 0.499; p = 0.68 OR = 0.001; p = 0.554 
PIIINP [pg/mL] OR = 1.00007; p = 0.837 OR = 1.00006; p = 0.907 OR ≥ 100; p = 0.999
Col-1 [pg/mL] OR = 0.99735; p = 0.075 OR = 0.998; p = 0.368 OR ≤ 0.00001; p = 0.999
OPN [ng/mL] OR = 0.994; p = 0.953 OR = 0.908; p = 0.737 OR ≤ 0.00001; p = 1 
TGF-b1 [pg/mL] OR = 0.99975; p = 0.282 OR = 1.00002; p = 0.947 OR = 1.502; p = 0.99 
CTGF [ng/mL] OR = 1.025; p = 0.784 OR = 1.015; p = 0.916 OR ≥ 100; p = 0.91 
MMP-2 [ng/mL] OR = 1.249; p = 0.203 OR = 1.246; p = 0.346 OR ≥ 100; p = 0.998 
MMP-9 [pg/ml] OR = 1; p = 0.98 OR = 1.00007; p = 0.75 OR = 1.137; p = 0.993 
TIMP-1 [pg/mL] OR = 1.00002; p = 0.488 OR = 1.00002; p = 0.597 OR = 1.033; p = 0.991
NT-proBNP — N-terminal pro B-type natriuretic peptide; OR — odds ratio; other abbreviations — see Table 2
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25 were differentially expressed when comparing 
the LA and LV. In line with this, Zhang et al. [20] 
reported that 169 microRNAs were expressed at 
different levels in the human RA and RV myocar-
dium. Unfortunately, there are no studies directly 
comparing the microRNA profile between LV and 
RV. Still, recent studies have shown that circulating 
microRNAs reflect tissue microRNAs. De Rosa et 
al. [21] and Melman et al. [22], who studied trans-
coronary gradients of microRNAs levels, provided 
evidence that miR-133 and miR-30 are directly 
released from the heart. Li et al. [23] showed 
that 36 microRNAs were expressed differently in 
patients with a ventricular septal defect compared 
to controls, and the majority of those microRNAs 
targeted genes related to RV morphogenesis. Also, 
Sucharow et al. [24] observed different microRNA 
profiles in pediatric patients with hypoplastic left 
heart syndrome in comparison to pediatric and 
adult patients with DCM. Similarly, Lai et al. [25] 
found 11 microRNAs that were significantly in-
creased in patients after an atrial switch operation 
for complete transposition of the great arteries 
(TGA) compared to healthy controls. In contrast to 
these findings, Tutarel et al. [26] did not observe 
any differences in levels of circulating miR-423-5p 
between patients with a systemic RV and reduced 
EF after atrial repair for TGA and controls. In 
another study, Satoh et al. [27] reported an as-
sociation between miR-208, cardiac fibrosis and 
outcomes in DCM, but no associations between 
microRNAs and ECM fibrosis.
Surprisingly, a comparison of the expres-
sion levels of fibrosis-linked microRNAs in DCM 
patients with and without RV morphological and/ 
/or functional abnormalities has not yet been 
performed. Thus, reported herein for the first 
time, that miR-133a was the sole microRNA ex-
pressed differently in patients with preserved and 
abnormal RV. All microRNAs, except for miR-29, 
correlated with various RV diameters, RA area, 
and PASP. Importantly, none of the microRNAs 
correlated with RV systolic function parameters. 
Current research indicates that microRNAs may 
also serve as predictive parameters, as confirmed 
by Devaux et al. [28] who reported that a panel 
of four microRNAs, including miR-16, miR-27a, 
miR-101 and miR-150 improved the prediction of 
LV contractility in patients after acute myocardial 
infarction. In addition, it was recently observed 
that following circulating microRNAs: miR-3135b, 
mir-3908 and miR-5571-5p may also serve as 
potential as diagnostic markers in DCM [29]. 
Therefore, in order to clarify the as-yet-ambigu-
ous issue of the relationship between the various 
microRNAs, we researched RV morphological and 
functional parameters, the logistic regression 
analyses assessed the added predictive value of 
these microRNAs against multi-parameter clinical 
models, including established predictors of RV 
morphology and function. The results obtained 
showed that miR-30 alone was associated with 
RV impairment in unadjusted model but lost its 
significance in the more comprehensive model. 
Limitations of the study
Although we sampled up to five biopsies along 
the RV interventricular septum, the presence of 
fibrosis was assessed in 2–3 samples, thus, the 
possibility  cannot excluded that, due to the patchy 
distribution of fibrosis, this assessment may not 
be completely accurate. On the other hand, ECM 
fibrosis was confirmed in 24 (34.3%) patients and 
CVF was 5.88 ± 6.06% — findings that are consist-
ent with other studies. The distribution of patients 
with normal and abnormal RV was uneven (15 vs. 
55 patients), which may influence the robustness 
of statistical analyses. Patients who developed 
abnormal RV suffered from DCM for a significantly 
longer period than those with normal RV (29.8 ± 
± 38.3 vs. 4.1 ± 5.7 months, p < 0.001, respectively). 
Consequently, those patients had significantly 
increased incidence of CRT-D implantation (25 
[45.5%] with RVD and/or RVSD vs. 2 [13.3%] 
without RVD and/or RVSD, p < 0.02, respectively), 
which is a proven intervention that reverses left 
and right ventricular remodeling. 
Conclusions
Right ventricle dilation and/or systolic dys-
function were common and were observed in more 
than three-quarters of the DCM cohort. Invasive-
ly-determined ECM fibrosis as well as serum 
markers of fibrosis are not useful in predicting 
RV abnormalities. The expression of circulating 
microRNAs, with the exception of miR-133a, was 
similar in DCM patients regardless of RV dila-
tion and/or systolic impairment. The microRNAs 
miR-21, miR-26, miR-30a, and miR-133a corre-
lated with various RV morphological parameters; 
however, none of the microRNAs correlated with 
RV systolic function indices. Mir-30 was associ-
ated with RV impairment in the logistic regression 
model adjusted for age, sex, BMI, and disease 
duration; however, this association was no longer 
observed in the most comprehensive model that 
was adjusted for more powerful RV-associated 
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variables. The prognostic value of the microRNAs 
researched in this paper on RV morphology and 
function is limited in DCM. 
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